Brief: Atossa Therapeutics, Quantum Leap Healthcare Provides Enrollment Update
28/06/2023 14:33
June 28 (Reuters) - Atossa Therapeutics Inc ATOS.O :
* ATOSSA THERAPEUTICS AND QUANTUM LEAP HEALTHCARE PROVIDE
ENROLLMENT UPDATE FOR (Z)-ENDOXIFEN ARM OF ONGOING I-SPY 2
CLINICAL TRIAL
* ATOSSA THERAPEUTICS - 6 PATIENTS DOSED WITH CO'S
PROPRIETARY
SELECTIVE ESTROGEN RECEPTOR MODULATOR (Z)-ENDOXIFEN, IN PHASE 2
I-SPY 2 CLINICAL TRIAL
Source text for Eikon: ID:nPnb03zs3a
Further company coverage: ATOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary